We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Pen-Like Device for Real Time Tissue Analysis to Revolutionize Surgical Pathology

By LabMedica International staff writers
Posted on 04 May 2023
Print article
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)

For over a century, cancer tissue analysis has depended on long-established workflows, with traditional histopathology results typically taking 40 minutes or more. In this process, tissue is biopsied, sent to a lab, frozen, sliced, stained, and examined by a pathologist under a microscope. While awaiting results, the patient remains under anesthesia, increasing their risk of infection and incurring additional costs for both the patient and hospital. Now, a groundbreaking device incorporating cutting-edge mass spectrometry and artificial intelligence (AI) can identify cancerous tissue—in vivo and ex vivo—within just 10 seconds, empowering surgeons, oncologists, and healthcare providers with real-time decision-making capabilities.

The MasSpec Pen System from MS Pen Technologies (Houston, TX, USA) is a proprietary, user-friendly, disposable, and biocompatible device that facilitates rapid tissue analysis. This non-invasive pen-like instrument grants medical professionals access to sophisticated technology that was previously available only to specialists. The MasSpec Pen System ensures fast, precise and highly accurate tissue identification, both in vivo and ex vivo. The more cancer is removed, the less likely tumors will recur and the less likely patients will need adjuvant treatments.

The MasSpec Pen System requires only a small amount of water and three seconds of gentle contact, eliminating the need to destroy or remove healthy tissue. This results in improved precision, recovery periods, and outcomes. Probes from the disposable MasSpec pen connect directly to the mass spectrometer's console, which analyzes the droplet to generate a unique molecular fingerprint of the sample. Advanced data analytics and AI transform complex metabolic data into straightforward, actionable information. Predictive statistical models built from molecular data distinguish between normal and cancerous tissues. In 10 seconds or less, the software provides easily interpretable diagnostic results in real time.

With the MasSpec Pen System, medical professionals can characterize tissues without leaving the operating room or extracting tissue from the patient. This portable, battery-operated machine can be relocated as needed—whether to a patient room or just inches from the operating table. Due to its quick and non-invasive nature, the process can be repeated multiple times if suspicious tissue remains. By eliminating the need for repeated invasive pathology results, the MasSpec Pen System significantly reduces procedure times, decreases extended anesthesia use, lowers the risk of infection, and minimizes financial burdens for both patients and hospital systems.

Related Links:
MS Pen Technologies 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.